한빛사논문
- 조회190
Hyemin Jang 1,2, Min Young Chun 1,3,4, Jihwan Yun 1,5, Jun Pyo Kim 1,6, Sung Hoon Kang 7, Michael Weiner 8, Hee Jin Kim 1,6,9,10, Duk L Na 1,6, Chang-Hyung Hong 11, Sang Joon Son 11, Hyun Woong Roh 11, Tae-Kyeong Lee 5, Eek-Sung Lee 5, Eun Hye Lee 1, Daeun Shin 1, Hongki Ham 1,6, Yuna Gu 1,9, Yeshin Kim 12, Chi-Hun Kim 13, Sook-Young Woo 14, Sang Won Seo 1,6,9,10; ADNI, A4 study, and K‐ROAD study groups
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.
2Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea.
3Department of Neurology, Yonsei University College of Medicine, Seodaemun-gu, Seoul, South Korea.
4Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin-si, Gyeonggi-do, South Korea.
5Department of Neurology, Soonchunhyang University Bucheon Hospital, Bucheon-si, Gyeonggi-do, South Korea.
6Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Gangnam-gu, Seoul, South Korea.
7Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul, South Korea.
8Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
9Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea.
10Department of Digital Health, SAIHST, Sungkyunkwan University, Gangnam-gu, Seoul, South Korea.
11Department of Psychiatry, Ajou University School of Medicine, Ajou University Hospital, Suwon-si, Gyeonggi-do, South Korea.
12Department of Neurology, Kangwon National University School of Medicine, Gangwon-do, South Korea.
13Department of Neurology, Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, South Korea.
14Biomedical Statistics Center, Data Science Research Institute, Samsung Medical Center, Gangnam-gu, Seoul, South Korea.
Hyemin Jang, Min Young Chun, and Jihwan Yun contributed equally to this work and shared the first authorship.
Sang Won Seo and Sookyoung Woo contributed equally to this article as co-corresponding authors
Abstract
Introduction: We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans and non-Hispanic Whites (NHWs).
Methods: We included 5121 Koreans from multiple centers across South Korea and 929 NHWs from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants underwent Aβ positron emission tomography and were categorized into cognitively unimpaired (CU), mild cognitive impairment (MCI), and dementia stages. Age, sex, education, and apolipoprotein E. genotype were adjusted using multivariable logistic regression and stabilized inverse probability of treatment weights based on the propensity scores to mitigate imbalances in these variables.
Results: The prevalence of Aβ+ was lower in CU Koreans than in CU NHWs (adjusted odds ratio 0.60). Aβ+ Koreans showed a faster cognitive decline than Aβ+ NHWs in the CU (B = -0.314, p = .004) and MCI stages (B = -0.385, p < .001).
Discussion: Ethnic characteristics of Aβ biomarkers should be considered in research and clinical application of Aβ-targeted therapies in diverse populations.
Highlights: Koreans have a lower prevalence of Aβ positivity compared to NHWs in the CU stage. The effects of Alzheimer's risk factors on Aβ positivity differ between Koreans and NHWs. Aβ-positive (Aβ+) Koreans show faster cognitive decline than Aβ+ NHWs in the CU and MCI stages.
논문정보
- Research article
- 2024년 09월 (BRIC 등록일 2024-09-25)
- 국내 연구진
- 의약학 > 신경의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
